Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Aegon Ltd. (AEG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Aegon Ltd. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.76 (market cap $4.49B), while Aegon Ltd. trades at $8.72 (market cap $12.98B). The key difference: Aegon Ltd. is far larger — about 2.9× ACADIA Pharmaceuticals Inc.'s market cap, and Aegon Ltd. pays a 5.3% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | AEG | |
|---|---|---|
Market Cap | $4.49B | $12.98B |
Sector | Health | Financials |
52-Week High | $28.06 | $8.79 |
52-Week Low | $20.06 | $6.79 |
Enterprise Value | $3.69B | $14.11B |
Dividend Yield | — | 5.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
AEG trades at $8.75, up 1.04% on the day, with a P/E of 12.86 and P/S of 0.55 indicating potential undervaluation. Recent earnings show mixed results, beating estimates in Q2 and Q3 2025 but missing in Q4. The company is undergoing strategic simplification, including moving its legal seat to Delaware and focusing on U.S. operations, supported by a dividend of $0.25 payable in July 2026. Technical indicators are bullish on moving averages but neutral on oscillators.
Outlook is cautiously optimistic with a 27.78% analyst buy rating, driven by restructuring benefits and U.S. market focus. Risks include execution challenges in the transition, volatile cash flows, and competitive pressures. The stock presents a value opportunity if the strategic pivot succeeds, but investors should monitor earnings consistency and debt management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Aegon Ltd.
Aegon is a Netherlands-headquartered insurance company with core operations that stretch across the U.S., Netherlands, and United Kingdom. The business also holds peripheral ventures in Spain, Portugal, Brazil, and China.
Read more on AEG →
